跳至主要内容
临床试验/IRCT2017041533448N1
IRCT2017041533448N1已完成未知

Evaluation of comparative effect of intravitreal bevasizumab on visual acuity and central macular thickness in patient with central serous chorioretinopathy

Vice chancellor for research, Zahedan University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Patients with visual loss (2 lines Snellen chart or more) and in scan (the thickness of the central part of the macula greater than 250 microns) diagnosis of central serous chorioretinopathy they laid is.
  • Exclusion criteria: Patient with visual loss with pathological retinal diseases other than Central serous retinopathy and diabetic retinopathy and hypertensive retinopathy and retinal dystrophies and patients who do not have the desire to enter the study.

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Zahedan University of Medical Sciences

相似试验